Literature DB >> 3816953

Disposition of apomorphine in rat brain areas: relationship to stereotypy.

G Bianchi, M Landi, S Garattini.   

Abstract

Apomorphine-induced stereotyped behavior and apomorphine levels in plasma, striatum and nucleus accumbens were determined in rats at various intervals after a single i.p. injection of serial doses of apomorphine hydrochloride (0.625, 1.25, 2.5 and 5 mg/kg). Apomorphine disappeared from plasma in a mono-exponential mode with a half-life of about 10 min. In striatum and nucleus accumbens apomorphine concentrations peaked 10 min after administration, declining thereafter with a half-life comparable to that in plasma. Apomorphine was concentrated and distributed similarly in the two brain regions; the brain areas/plasma ratio was approximately seven for all doses tested. The rise of apomorphine levels in brain areas slightly preceded the behavioral response, whereas after the peak effect (20-30 min) the intensity of stereotypy declined almost parallel with the log drug concentrations. Plotting apomorphine levels in the tissues assayed against the drug response at the same interval for individual rats, regardless of dose, indicated a highly significant relation between the degree of behavioral effects and brain apomorphine levels. The threshold apomorphine concentrations for inducing stereotyped behaviour were 108 and 95 ng/g respectively in striatum and nucleus accumbens. These findings show that the time course and magnitude of the behavioral effects of apomorphine corresponded with its brain levels in 'dopaminergic' areas, suggesting that apomorphine-induced stereotyped behavior in rats can be described by a direct mechanism. Reserpine (5 mg/kg s.c.) enhanced the apomorphine stereotypy but did not affect apomorphine's disposition in brain and plasma.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3816953     DOI: 10.1016/0014-2999(86)90576-5

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  6 in total

1.  Behavioural profile of Wistar rats with unilateral striatal lesion by quinolinic acid (animal model of Huntington disease) post-injection of apomorphine and exposure to static magnetic field.

Authors:  Carolina Giorgetto; Elaine Cristina Mazzei Silva; Takae Tamy Kitabatake; Guilherme Bertolino; João Eduardo de Araujo
Journal:  Exp Brain Res       Date:  2015-02-11       Impact factor: 1.972

2.  Subcutaneous apomorphine increases regional cerebral blood flow in parkinsonian patients via peripheral mechanisms.

Authors:  U Sabatini; O Rascol; P Celsis; G Houin; A Rascol; J P Marc-Vergnes; J L Montastruc
Journal:  Br J Clin Pharmacol       Date:  1991-08       Impact factor: 4.335

3.  The metabotropic glutamate 2/3 receptor agonist LY379268 counteracted ketamine-and apomorphine-induced performance deficits in the object recognition task, but not object location task, in rats.

Authors:  Nikolaos Pitsikas; Athina Markou
Journal:  Neuropharmacology       Date:  2014-05-20       Impact factor: 5.250

4.  Imaging apomorphine stimulation of brain arachidonic acid signaling via D2-like receptors in unanesthetized rats.

Authors:  Abesh Kumar Bhattacharjee; Lisa Chang; Laura White; Richard P Bazinet; Stanley I Rapoport
Journal:  Psychopharmacology (Berl)       Date:  2008-02-15       Impact factor: 4.530

5.  Neurorestorative effects of sub-chronic administration of ambroxol in rodent model of Parkinson's disease.

Authors:  Akanksha Mishra; Sairam Krishnamurthy
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2019-10-25       Impact factor: 3.000

6.  S[+] Apomorphine is a CNS penetrating activator of the Nrf2-ARE pathway with activity in mouse and patient fibroblast models of amyotrophic lateral sclerosis.

Authors:  Richard J Mead; Adrian Higginbottom; Scott P Allen; Janine Kirby; Ellen Bennett; Siân C Barber; Paul R Heath; Antonio Coluccia; Neelam Patel; Iain Gardner; Andrea Brancale; Andrew J Grierson; Pamela J Shaw
Journal:  Free Radic Biol Med       Date:  2013-04-19       Impact factor: 7.376

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.